I am a science-driven and results-oriented scientist with 10 years of research experience in the field of protein engineering, molecular and cancer biology. I am currently Research Scientist in the Technology Discovery team at Kymab, supporting the development of novel therapeutic antibodies to treat diseases with severe unmet medical need. I am focusing on the development of next generation of bispecific antibodies by integrating bioinformatics, pre-clinical datasets and Kymab IntelliSelect discovery platform.As Translational Scientist in BioMarin I supported the translation of scientific concepts into novel therapeutics approaches. I focussed on the identification of novel disease and pharmacodynamic biomarkers for neuromuscular diseases to obtain a better understanding the mechanisms underlying the disease and to assess the efficacy of novel therapeutic approaches. To achieve this goal I integrated genomic, transcriptomic and proteomic large datasets with pre-clinical data and data mining.At the Hubrecht Institute, one of the top biomedical research institutes in the field of Cancer Stem Cells, I developed high throughput proteomic screens to identify novel substrates of the E3 ubiquitin ligases, crucial enzymes for the maintenance of cell homeostasis and frequently mutated in multiple types of cancer. I also set up diverse in vivo and in vitro cell-based assays to characterize the molecular effects of the newly identified targets in cancer development. A number of identified substrates can represent potential drug targets for anti-cancer therapy.With my expertise in biomedical research, I am well-qualified to support the discovery and translation into clinic of innovative therapies for cancer and other life-threatening diseases.